Copenhagen, Denmark, 21 January 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, today announces that it has become a member of Medicines for Europe, effective January 1st 2021.
Generic, biosimilar and value-added medicines currently account for 70% of essential medicines prescribed in Europe, needed daily to help patients manage acute and chronic diseases such as cancer, auto-immune and respiratory conditions1. Off-patent and repurposed medicines are also a key part of the COVID-19 response, facilitating patient treatment in hospital emergency units globally.
Medicines for Europe (formerly European Generics Medicines Association) represents the generic, biosimilar and value-added pharmaceutical industries in Europe. Member companies are responsible for providing the essential medicines that European patients, healthcare professionals and healthcare systems rely on, increasing access and driving improved health outcomes.
With more than 115 years of experience, Xellia is a leading supplier of critical established anti-infective drugs for serious bacterial and antibiotic-resistant infections, and fungal diseases. Although active pharmaceutical ingredient (API) manufacturing forms the backbone of the business, Xellia has also invested significantly in R&D to create an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals. The Company’s products aim to solve unmet medical needs in the increasingly challenging anti-infective therapeutic area.
Carl-Åke Carlsson, CEO & President, Xellia Pharmaceuticals said: “At Xellia, we have patient needs at the center of all our efforts. We focus on supplying consistently through our global vertical integration strategy and by improving supply security through multiple sources of in-house production of our APIs and drug products. We hold great pride in that our products are affordable and accessible globally.
Acceptance into Medicines for Europe is great recognition of our work and will enable Xellia to unite with likeminded companies also working to secure access to quality medicines for patients in Europe. Better access to the most effective therapies means millions more patients will receive the treatments they need, providing long-term benefits for society. This is well aligned with Xellia’s purpose to save and enhance lives by leading the fight against infections.”
Adrian van den Hoven, Director General of Medicines for Europe, commented: “Medicines for Europe is excited to have Xellia join industry-wide efforts to increase access to effective medicines, improve security of supply and engage on critical public health issues such as anti-microbial resistance. Generic and value-added medicines development are critical to tackling these public health challenges.”
About Xellia Pharmaceuticals
Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.
With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.
Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.
For more information, please contact: email@example.com